With 74% Ownership, Accolade, Inc. (NASDAQ:ACCD) Boasts of Strong Institutional Backing
Press Release: Accolade to Announce Fiscal Second Quarter 2025 Financial Results
D.A. Davidson Maintains Accolade(ACCD.US) With Hold Rating
BofA Securities Maintains Accolade(ACCD.US) With Buy Rating, Announces Target Price $7
First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies
Express News | Accolade Shares Are Trading Higher Following a Report Suggesting the Company Is Exploring a Sale
Express News | Watching Accolade; Shares Spike Higher As Traders Circulate The Company Is Exploring A Sale
Accolade To Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
Leerink Partners Maintains Accolade(ACCD.US) With Buy Rating, Maintains Target Price $9.5
Wells Fargo Maintains Accolade(ACCD.US) With Hold Rating, Maintains Target Price $7
BofA Securities Maintains Accolade(ACCD.US) With Buy Rating
Accolade, Inc. (ACCD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Express News | Accolade Inc : Jefferies Cuts Target Price to $4 From $9
Express News | Accolade Inc : Raymond James Cuts Target Price to $11 From $16
Express News | Accolade Inc : Stephens Cuts Target Price to $10 From $14
Earnings Release: Here's Why Analysts Cut Their Accolade, Inc. (NASDAQ:ACCD) Price Target To US$8.47
BofA Securities Maintains Accolade(ACCD.US) With Buy Rating, Cuts Target Price to $7
A Quick Look at Today's Ratings for Accolade(ACCD.US), With a Forecast Between $7 to $9
Sector Update: Health Care Stocks Decline in Late Afternoon Trading
Sector Update: Health Care